Home › Urinary Tract Infections › NCT05227937
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Single Dose Amikacin for Uncomplicated Cystitis in the Emergency Department (ED): A Feasibility Study
Who can join
Ages 14 to 110 · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * female emergency medicine patients * ≥14 years of age * uncomplicated urinary tract infection * a primary urinary complaint and nitrite-positive urine. Exclusion Criteria: * pregnancy * abnormal genitourinary tract * recent urinary tract instrumentation * immunosuppression * CrCl \< 25 mL/min * evidence of pyelonephritis or sepsis * any antibiotic treatment within 30 days * not available for phone follow-up in 3, 7, and 30 days * requires admission to the hospital * abnormal mental status.
About the study
The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, and then take antibiotics for 3-7 days. A single dose of amikacin has been demonstrated to be safe, effective and well tolerated in other studies, but some patients may decline to participate because they do not wish to have an IV or IM shot, or because they don't want to speak on the phone with a research assistant three times over the next 30 days.
What is being tested
- Amikacin (drug)
Sponsor: Antonios Likourezos · Participants: 75 · Started: Sep 21, 2022
Contact the study team
- Reuben Strayer, MD · Phone: 718-283-6000
- Antonios Likourezos, MA, MPH · Phone: 718-283-6896
Official record on ClinicalTrials.gov — NCT05227937
Locations in the U.S.
| New York | Maimonides Medical Center, Brooklyn |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.